4.7 Article Book Chapter

The tuberous sclerosis complex

期刊

YEAR IN NEUROLOGY 2
卷 1184, 期 -, 页码 87-105

出版社

WILEY-BLACKWELL
DOI: 10.1111/j.1749-6632.2009.05117.x

关键词

tuberous sclerosis complex (TSC); focal cortical malformations (FCMs); TSC1 genes; TSC2 genes; rapamycin

资金

  1. NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F30NS064631, R01NS048557] Funding Source: NIH RePORTER
  2. NINDS NIH HHS [R01 NS048557, F30 NS064631-01A1, R01 NS048557-05, R01NS04502] Funding Source: Medline

向作者/读者索取更多资源

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder that results from mutations in the TSC1 or TSC2 genes and is associated with hamartoma formation in multiple organ systems. The neurological manifestations of TSC are particularly challenging and include infantile spasms, intractable epilepsy, cognitive disabilities, and autism. Progress over the past 15 years has demonstrated that the TSC1 or TSC2 encoded proteins modulate cell function via the mTOR signaling cascade and serve as keystones in regulating cell growth and proliferation. The mTOR pathway provides an intersection for an intricate network of protein cascades that respond to cellular nutrition, energy levels, and growth-factor stimulation. In the brain, TSC1 and TSC2 have been implicated in cell body size, dendritic arborization, axonal outgrowth and targeting, neuronal migration, cortical lamination, and spine formation. Antagonism of the mTOR pathway with rapamycin and related compounds may provide new therapeutic options for TSC patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据